Alpharma has acquired certain assets of Yantai JinHai Pharmaceutical in China. The company's Animal Health business plans to utilize this site to blend products it currently processes in its US facilities and sells in Asia. The purchase of these assets is expected to provide supply chain flexibility, and expand the company's regulatory base in Asia.
 
The acquisition includes product registrations the company plans to utilize to expand its Asian product offering. This transaction is not expected to have a material impact on the company’s 2007 operating results.
 
“In our Animal Health and API businesses, we are targeting strategic investments in China that we believe over time will improve our supply chain and establish a presence in this important global market,” said Mr Dean Mitchell, President and Chief Executive Officer.